Trends in ventricular fibrillation/flutter mortality in US population, 1999 to 2019.
mortality
trend
ventricular arrhythmias
Journal
Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
19
05
2023
received:
16
01
2023
accepted:
03
06
2023
medline:
14
7
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
ppublish
Résumé
The Ventricular fibrillation and flutter (VF/VFL)-related mortality trends in the United States (US) population have not yet been investigated. We aimed to assess the trends of VT/VFL-related mortality from 1999 to 2019 among subjects aged more than 15 years old in the US. Data derived from the Centers for Disease Control and Prevention's (CDC) WONDER were analyzed between 1999 and 2019 for VF/VFL-related mortality in subjects aged more than 15 years of age. Adjusted mortality rates (AAMRs) per 100,000 people by year, sex, race and urban-rural status with relative confidence intervals (CIs) were determined. Both the average annual percent change (AAPC) and the annual percent change (APC) with 95% Cis were calculated. Between 1999 and 2019, 242,125 VT/VFL-related deaths occurred in the US. The overall AAMR steadily declined [AAPC -4.4% (95% CI: -4.7 to -4.0, p < .0001)]. Women showed a more pronounced AAMRs decline [AAPC: -4.8% (95% CI: -5.3 to -4.3, p < .0001). AAMR steadily declined in white subjects and in those of other races [AAPC: -4.5 (95% CI: -4.7 to -4.2, p < .0001) and AAPC: -4.3 (95% CI: -5.1 to -3.5, p < .001), respectively]. Conversely, African Americans showed a steadily AMMR decline between 1999 and 2007 [APC: -8.3 (95% CI: -9.2 to -7.3, p < .0001)], followed by a period of stability from 2007 to 2019 (p = .73). A similar decline was observed for the AAMR among subjects living in urban and rural areas. VT/VFL-related mortality steadily decreased between 1999 and 2019 in US. Despite the encouraging results, further efforts are needed to prevent VF/VFL-related mortality in US subjects.
Sections du résumé
BACKGROUND
The Ventricular fibrillation and flutter (VF/VFL)-related mortality trends in the United States (US) population have not yet been investigated. We aimed to assess the trends of VT/VFL-related mortality from 1999 to 2019 among subjects aged more than 15 years old in the US.
METHODS
Data derived from the Centers for Disease Control and Prevention's (CDC) WONDER were analyzed between 1999 and 2019 for VF/VFL-related mortality in subjects aged more than 15 years of age. Adjusted mortality rates (AAMRs) per 100,000 people by year, sex, race and urban-rural status with relative confidence intervals (CIs) were determined. Both the average annual percent change (AAPC) and the annual percent change (APC) with 95% Cis were calculated.
RESULTS
Between 1999 and 2019, 242,125 VT/VFL-related deaths occurred in the US. The overall AAMR steadily declined [AAPC -4.4% (95% CI: -4.7 to -4.0, p < .0001)]. Women showed a more pronounced AAMRs decline [AAPC: -4.8% (95% CI: -5.3 to -4.3, p < .0001). AAMR steadily declined in white subjects and in those of other races [AAPC: -4.5 (95% CI: -4.7 to -4.2, p < .0001) and AAPC: -4.3 (95% CI: -5.1 to -3.5, p < .001), respectively]. Conversely, African Americans showed a steadily AMMR decline between 1999 and 2007 [APC: -8.3 (95% CI: -9.2 to -7.3, p < .0001)], followed by a period of stability from 2007 to 2019 (p = .73). A similar decline was observed for the AAMR among subjects living in urban and rural areas.
CONCLUSIONS
VT/VFL-related mortality steadily decreased between 1999 and 2019 in US. Despite the encouraging results, further efforts are needed to prevent VF/VFL-related mortality in US subjects.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
796-802Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:948-954.
Koplan BA, Stevenson WG. Ventricular tachycardia and sudden cardiac death. Mayo Clin Proc. 2009;84:289-297.
Deal BJ, Miller SM, Scagliotti D, Prechel D, Gallastegui JL, Hariman RJ. Ventricular tachycardia in a young population without overt heart disease. Circulation. 1986;73:1111-1118.
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American college of Cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Heart Rhythm. 2018;15:e190-e252.
Centers for Disease Control and Prevention National Center for Health Statistics. Multiple Cause of Death Accessed September 1, 2022. [Available from: https://wonder.cdc.gov/mcd.html]
US Census Bureau Population Division. Monthly population estimates by age, sex, race, and hispanic origin for the United States: April 1, 2010 to July 1, 2019 (with short-term projections to December 2020) June 2020. https://www.census.gov/data/datasets/time-series/demo/popest/intercensal-2000-2010-national.html
Rossen LM, Nørgaard SK, Sutton PD, et al. Excess all-cause mortality in the USA and Europe during the COVID-19 pandemic, 2020 and 2021. Sci Rep. 2022;12:18559.
National Cancer Institute. Number of Joipoints. [Accessed September 29,2022] https://surveillance.cancer.gov/help/joinpoint/setting-parameters/method-and-parameters-tab/number-of-joinpoints
Movahed MR, Hashemzadeh M, Jamal M. Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus. Heart Vessels. 2007;22:251-253.
Remme CA. Sudden Cardiac death in diabetes and obesity: mechanisms and therapeutic strategies. Can J Cardiol. 2022;38:418-426.
Fishman GI, Chugh SS, DiMarco JP, et al. Sudden cardiac death prediction and prevention: report from a National heart, lung, and blood institute and heart rhythm society workshop. Circulation. 2010;122:2335-2348.
Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation. 2002;106:309-312.
Glynn P, Lloyd-Jones DM, Feinstein MJ, Carnethon M, Khan SS. Disparities in cardiovascular mortality related to heart failure in the United States. J Am Coll Cardiol. 2019;73:2354-2355.
Tanaka Y, Shah NS, Passman R, Greenland P, Lloyd-Jones DM, Khan SS. Trends in cardiovascular mortality related to atrial fibrillation in the United States, 2011 to 2018. J Am Heart Assoc. 2021;10:e020163.
Ye Y, Larrat EP, Caffrey AR. Algorithms used to identify ventricular arrhythmias and sudden cardiac death in retrospective studies: a systematic literature review. Ther Adv Cardiovasc Dis. 2018;12:39-51.
Hennessy S, Leonard CE, Palumbo CM, Bilker WB, Newcomb C, Kimmel SE. Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's general practice research database. Pharmacoepidemiol Drug Saf. 2008;17:1131-1136.
Zambon A, Polo Friz H, Contiero P, et al. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf. 2009;32:159-167.
Bunch TJ, White RD. Trends in treated ventricular fibrillation in out-of-hospital cardiac arrest: ischemic compared to non-ischemic heart disease. Resuscitation. 2005;67:51-54.
Mensah GA, Wei GS, Sorlie PD, et al. Decline in cardiovascular mortality: possible causes and implications. Circ Res. 2017;120:366-380.
Stevenson WG. Current treatment of ventricular arrhythmias: state of the art. Heart Rhythm. 2013;10:1919-1926.
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793-2867.
Santangeli P, Muser D, Maeda S, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016;13:1552-1559.
Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119(18):2426-2434.
Sheikh N, Papadakis M, Panoulas VF, et al. Comparison of hypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the UK. Heart. 2016;102:1797-1804.
Eberly LA, Day SM, Ashley EA, et al. Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2020;5:83-91.
Patel HP, Thakkar S, Mehta N, et al. Racial disparities in ventricular tachycardia in young adults: analysis of national trends. J Interv Card Electrophysiol. 2023;66(1):193-202. doi:10.1007/s10840-022-01335-5
Jolly S, Vittinghoff E, Chattopadhyay A, Bibbins-Domingo K. Higher cardiovascular disease prevalence and mortality among younger blacks compared to whites. Am J Med. 2010;123:811-818.
Rooks RN, Simonsick EM, Klesges LM, Newman AB, Ayonayon HN, Harris TB. Racial disparities in health care access and cardiovascular disease indicators in Black and White older adults in the Health ABC Study. J Aging Health. 2008;20:599-614.